ProKidney (PROK) Projected to Post Quarterly Earnings on Monday

Key Points

• ProKidney is expected to report Q3 2026 results on November 9, with analysts forecasting a loss of $0.13 per share and revenue of $0.12 million. The earnings call is scheduled for November 10 at 4:00 p.m. ET.
• The company previously missed estimates, reporting a $0.15-per-share loss and $0.15 million in revenue versus expectations of a $0.14 loss and $0.19 million in revenue.
• Shares opened at $1.29, near their one-year low, while analyst sentiment remains a “Moderate Buy” with a $10 average price target. However, insiders have sold 757,164 shares over the past 90 days, and ProKidney has no approved commercial product as it develops its rilparencel kidney-disease therapy.

ProKidney (NASDAQ:PROK - Get Free Report) is anticipated to issue its Q3 2026 resultson Monday, November 9th. Analysts expect ProKidney to post earnings of ($0.13) per share and revenue of $0.12 million for the quarter. Investors can check the company's upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 4:00 PM ET.

ProKidney (NASDAQ:PROK - Get Free Report) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.01). The company had revenue of $0.15 million during the quarter, compared to analysts' expectations of $0.19 million. On average, analysts expect ProKidney to post ($0.51) EPS for the current fiscal year and ($0.75) EPS for the next fiscal year.

ProKidney Price Performance

Shares of NASDAQ PROK opened at $1.29 on Monday. The business's fifty day moving average price is $1.67 and its two-hundred day moving average price is $1.82. The firm has a market capitalization of $391.50 million, a PE ratio of -2.35 and a beta of 1.90. ProKidney has a 1-year low of $1.29 and a 1-year high of $3.13.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of ProKidney in a research report on Tuesday, October 6th. Citigroup cut their target price on ProKidney to $8.00 and set a "buy" rating for the company in a research report on Wednesday, October 28th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $10.00.

Insider Activity

In related news, Director Brian Pereira sold 222,948 shares of the firm's stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $1.42, for a total transaction of $316,586.16. Following the sale, the director directly owned 54,103 shares in the company, valued at $76,826.26. This trade represents a 80.47% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders have sold a total of 757,164 shares of company stock worth $1,067,315 over the last ninety days. 39.83% of the stock is owned by corporate insiders.

About ProKidney

ProKidney Corporation is a biotechnology company focused on developing cell-based therapies for chronic kidney disease (CKD). The company's lead investigational product is rilparencel, formerly known as REACT, an autologous cell therapy made from a patient's own kidney cells.

Rilparencel is designed to be injected into the patient's kidneys, where the cells are intended to support kidney function and potentially slow the progression of CKD. ProKidney is studying the therapy primarily in patients with diabetic kidney disease and advanced CKD, with the goal of delaying or reducing the need for dialysis or kidney transplantation.

ProKidney's operations are centered on the development and clinical testing of rilparencel, and the company does not currently have an approved commercial product.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.